Oncolytics Biotech (TSE:ONC) Shares Cross Above Two Hundred Day Moving Average – Here’s Why

Oncolytics Biotech Inc. (TSE:ONC) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of C$11.65 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares.

Oncolytics Biotech Stock Down 1.3%

The company has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The business’s 50 day moving average price is C$14.90 and its 200-day moving average price is C$11.65.

Oncolytics Biotech (TSE:ONC) last released its quarterly earnings results on Wednesday, November 12th. The company reported C($0.14) EPS for the quarter. On average, analysts anticipate that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.